Board of Directors

  • David Hipkiss CEO and Director
  • Andy Bush COO and Director
  • Meinhard Schmidt Non-Executive Chairman

David Hipkiss

CEO and Director

David joined Enesi Pharma in September 2017 as CEO. Prior to Enesi, he was Chief Business Officer of Circassia Pharmaceuticals, and a member of its Senior Management Team with global group responsibility for all M&A, partnering and licensing activities.

Before joining Circassia, David was CEO and co-founder of Prosonix, a particle engineering-enabled respiratory product company, taking it from its establishment in 2006, raising more than £25 million from leading international life sciences investors and institutions over several financing rounds, through to its successful sale in 2015 to Circassia for £100 million.

He has more than 25 years of business development and licensing experience concerning cutting-edge technologies in high growth, complex, IP-rich environments, with a prime focus on the pharmaceutical industry.  He has also held a number of positions with increasing seniority at Air Products, Chiroscience /ChiroTech Technology Ltd, Ascot plc, Dow Pharma, and Accentus.

David holds a degree in Chemical Engineering from the University of Birmingham, UK

Andy Bush

COO and Director

Andy has more than 30 years’ experience in technical, commercial and operational management of international business, most recently in the pharmaceutical industry in drug development and commercialisation.

Andy was a co-founder of Prosonix and, as COO/CFO, he managed the establishment, development and growth of the business since its formation in 2006 to deliver key strategic elements of the business plan. The business was sold to Circassia in 2015 and Andy then assisted in the integration of the Prosonix business activities, while working in corporate development at Circassia to evaluate potential licensing, mergers and acquisition deals.

Prior to joining Prosonix, Andy was Operations Manager of the C3 Technology Business of Accentus and previously held senior positions in two AEA Technology businesses in change management and business transformation roles. Before that he enjoyed a highly successful 18-year career in BOC spanning technical, operations and commercial management and was responsible for winning several long-term, multi-million pound business contracts.

Andy holds a Bachelors’ Degree in Chemical Engineering and is a Chartered Engineer. He also holds a Masters’ Degree in Business Administration.

Meinhard Schmidt

Non-Executive Chairman

Meinhard is a MedTech industry executive and entrepreneur with more than 25 years’ broad international experience ranging from global General, Operations, Marketing and Innovation Management. He is currently active as the founder and CEO at mt:onyx, an established Swiss-based service organisation providing business partnering and business development in the area of Life Sciences, Diagnostics and Medical Devices industry.

His activities include investments in start-ups with active board engagement and management support, consulting investors on identification of opportunities in the global MedTech industry and helping start-ups to establish business partnerships. Prior to this, he worked as an executive at Straumann AG (CH), responsible for the world-wide “Digitalisation” of the Dental industry. Between 1998 and 2008, Meinhard was at Roche Diagnostics where he held various global senior leadership roles in Diabetes Care, Decentralized Solutions and was global Senior VP at Lab Diagnostics, which achieved the leading global position in the laboratory industry.

Meinhard has strong board level experience and has worked across M&A, global operations, sales and marketing, programme and innovation management and has held executive management positions in Germany, the Netherlands, USA, Canada, Sweden, UK and Switzerland. He currently serves as Board Director at several healthcare/diagnostic companies in UK, Sweden and Switzerland.